Market Overview

IRhythm Still Kicking After Shock Of Apple Competition

IRhythm Still Kicking After Shock Of Apple Competition
Related AAPL
5 Books That Inspired Steve Jobs, Bill Gates And Other Billionaires
Barron's Picks And Pans: 2019 Picks, Emerging Markets, Small Caps And More
Time To Connect The Dots (Stocks To Watch Podcast) (Seeking Alpha)
Benzinga's Top Upgrades, Downgrades For September 6, 2018
75 Biggest Movers From Yesterday

Irhythm Technologies Inc (NASDAQ: IRTC) dropped as much as 10.6 percent Wednesday after Apple Inc. (NASDAQ: AAPL) announced FDA approval for an ECG scanner in its Watch Series 4.

But as Street experts see it, the jolt is far from lethal — it’s galvanizing.

The Rating

JPMorgan analyst Robbie Marcus maintained an Overweight rating on iRhythm with a $100 price target.

The Thesis

By JPMorgan’s assessment, Apple’s FDA-sanctioned feature poses no competitive threat to iRhythm’s Zio XT or AT technology.

“We don’t see Apple turning the iWatch into a regulated medical device approved for clinical diagnosis,” the analyst said in a note. (See Marcus' track record here.)

“To be clear, the Apple Watch is approved for over-the-counter use and is not a continuous monitor.” 

The FDA said the Apple Watch is not a replacement for traditional diagnostic or treatment methods. Should Apple pursue such a label and place itself in direct competition with iRhythm, the process could slow Apple’s rate of innovation and subject its products to FDA regulation, according to JPMorgan.

At present, its specialty in preliminary, OTC screenings is seen to complement iRhythm technology.

“Instead, we expect that greater consumer preliminary screening for heart arrhythmias will only expand the number of patients seeking medical diagnosis, which, in turn, would benefit iRhythm,” Marcus said.

“If anything, this news could be seen as a win for the company, as more patients will be able to check their own heartbeat and then go into the office to be prescribed a Zio in order to get a more comprehensive analysis of their heart health.”

Price Action

At the time of publication, iRhythm shares were trading up more than 5 percent at $94.14. 

Related Links:

Fitbit's 'Test' Will Come In The Second Half, Says Bearish BofA

Apple Debuts Faster, More Durable iPhones; New Watch Enters Medical Device Territory

Latest Ratings for AAPL

Dec 2018DA DavidsonReiteratesBuyBuy
Dec 2018CitigroupMaintainsBuyBuy
Dec 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for AAPL
View the Latest Analyst Ratings

Posted-In: JPMorgan Robbie MarcusAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (AAPL + IRTC)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Preview: Adobe Systems

Mid-Morning Market Update: Markets Open Higher; Kroger Sales Miss Views